Oxytetracycline (Terramycin)

Oxytetracycline is a naturally occurring broad-spectrum tetracycline antibiotic with a long history of use in veterinary medicine, including treatment of various bacterial infections in dogs. Originally derived from the bacterium Streptomyces rimosus, this antibiotic has been available for decades and remains a useful therapeutic option for specific clinical situations. Oxytetracycline is marketed under several brand names, with Terramycin being among the most recognized in veterinary practice. The medication is available in multiple formulations including injectable solutions for systemic infections and ophthalmic ointments for eye infections, providing veterinarians with flexibility in treating different types of bacterial diseases.

The mechanism of action of oxytetracycline, like all tetracycline antibiotics, involves inhibition of bacterial protein synthesis. The drug binds to the 30S ribosomal subunit of susceptible bacteria, preventing the attachment of transfer RNA to the messenger RNA-ribosome complex. This action blocks the elongation of the growing peptide chain, effectively halting protein production and stopping bacterial growth. Oxytetracycline's bacteriostatic effect means it prevents bacterial multiplication rather than directly killing organisms, relying on the host's immune system to eliminate the pathogens. The antibiotic demonstrates activity against a broad range of gram-positive and gram-negative bacteria, as well as certain intracellular organisms including rickettsiae, chlamydiae, and mycoplasmas.

Oxytetracycline formulations available for canine use include injectable solutions for intramuscular or intravenous administration, ophthalmic ointments for topical application to the eyes, and in some regions, oral formulations. The injectable form is particularly useful when rapid attainment of therapeutic blood levels is needed or when oral medication is not feasible. Terramycin ophthalmic ointment is widely used for treating bacterial conjunctivitis and other eye infections in dogs. The frequency of administration varies by formulation and indication, with injectable preparations often given once or twice daily and ophthalmic ointment applied multiple times daily to affected eyes.

Oxytetracycline has an established safety profile in dogs when used according to veterinary guidance, though it is subject to the same general precautions applicable to all tetracycline antibiotics. The medication's long history of veterinary use has provided substantial clinical experience regarding its efficacy and potential adverse effects. Proper dosing, appropriate route of administration, and completion of the full treatment course are essential for achieving therapeutic success while minimizing risks. As with any antibiotic, veterinary supervision is required to ensure appropriate selection of the drug for the specific infection and to monitor for any complications during treatment.

Oxytetracycline ophthalmic preparations represent one of the most common applications of this antibiotic in canine medicine. Terramycin ophthalmic ointment is frequently prescribed for bacterial conjunctivitis, an infection of the membrane lining the eyelids and covering the white portion of the eye. Dogs with conjunctivitis typically present with red, irritated eyes, discharge that may be clear, mucoid, or purulent, and discomfort or squinting. The broad-spectrum activity of oxytetracycline makes it effective against many of the common bacterial pathogens causing eye infections in dogs. The ointment formulation provides sustained contact with the ocular surface and is generally well-tolerated by canine patients.

Systemic oxytetracycline, administered via injection, is used to treat various bacterial infections throughout the body. Respiratory tract infections, including bronchitis and pneumonia caused by susceptible organisms, may respond to oxytetracycline therapy. The medication has activity against Bordetella bronchiseptica, one of the primary causative agents of kennel cough, as well as Pasteurella and other respiratory pathogens. Urinary tract infections caused by susceptible bacteria represent another indication for systemic oxytetracycline use. The antibiotic achieves therapeutic concentrations in urine, allowing effective treatment of bladder and kidney infections.

Oxytetracycline has applications in treating tick-borne diseases in dogs, though it is generally not considered the first-line tetracycline for these conditions. Anaplasmosis, ehrlichiosis, and Rocky Mountain spotted fever, caused by various intracellular bacteria transmitted through tick bites, can be treated with oxytetracycline when other tetracyclines are unavailable. However, doxycycline and minocycline typically demonstrate superior tissue penetration and are more commonly selected for tick-borne disease treatment. Oxytetracycline may be considered when these preferred agents cannot be used or when injectable therapy is specifically indicated.

Skin and soft tissue infections represent additional indications for oxytetracycline therapy. Wound infections, abscesses, and cellulitis caused by susceptible bacteria may respond to treatment with this antibiotic. The injectable formulation allows rapid achievement of therapeutic drug levels in tissues, which can be advantageous for more serious soft tissue infections. Certain dental infections and oral diseases with bacterial components may also be treated with oxytetracycline as part of a comprehensive treatment plan.

Veterinarians select oxytetracycline based on various factors including the type and location of infection, the suspected or confirmed causative organism, and practical considerations such as the feasibility of oral versus injectable administration. The medication may be preferred when injectable antibiotic therapy is needed, when ophthalmic infection requires topical treatment, or when other tetracyclines are not available or appropriate. The established efficacy and safety profile of oxytetracycline, combined with its reasonable cost, maintains its place as a useful option in the veterinary antibiotic armamentarium.

Oxytetracycline dosing requires veterinary calculation based on the individual dog's body weight, the specific infection being treated, and the formulation being used. The tremendous size variation among dog breeds, ranging from tiny Chihuahuas to massive Great Danes, makes accurate weight-based dosing essential for both efficacy and safety. Your veterinarian will determine the appropriate dose, route of administration, and frequency for your dog's specific situation. Never attempt to estimate doses or use oxytetracycline products without professional guidance, as inappropriate dosing can result in treatment failure or adverse effects.

For injectable oxytetracycline formulations, typical dosing ranges fall between approximately 7 to 11 milligrams per kilogram of body weight, with administration frequency depending on the specific product used. Some long-acting injectable formulations are designed for less frequent dosing, while standard preparations may require once or twice daily administration. Intramuscular injection is the most common route for veterinary oxytetracycline, though intravenous administration may be used in certain clinical situations. Your veterinarian will select the appropriate injectable product and provide instructions for administration if you will be giving injections at home, though many injectable treatments are administered in the veterinary clinic.

Treatment duration with systemic oxytetracycline varies based on the type and severity of infection. Respiratory infections, urinary tract infections, and soft tissue infections typically require treatment courses ranging from one to three weeks, with the specific duration determined by clinical response. Tick-borne diseases, when treated with oxytetracycline, generally require longer courses of at least four weeks to ensure adequate elimination of intracellular pathogens. Your veterinarian will establish an appropriate treatment timeline and may adjust the duration based on follow-up examinations and any diagnostic testing performed to assess treatment response.

Ophthalmic oxytetracycline ointment has its own specific administration guidelines. The ointment is typically applied to the affected eye or eyes three to four times daily, though your veterinarian may recommend different frequencies based on the severity of infection. Before applying the ointment, gently clean any discharge from around the eye using a clean, damp cloth or gauze. Pull down the lower eyelid slightly to create a small pocket, then squeeze a small ribbon of ointment (approximately one-quarter to one-half inch) into this pocket. Allow your dog to blink, which distributes the medication across the eye surface. Avoid touching the tip of the tube to the eye or surrounding structures to prevent contamination.

If a dose of oxytetracycline is missed, administer it as soon as you remember unless it is close to the time for the next scheduled dose. In that case, skip the missed dose and continue with the regular schedule. Do not double up on doses to make up for missed ones. For ophthalmic preparations, maintaining a consistent application schedule helps ensure adequate drug levels on the eye surface. If you are unsure how to proceed after missing doses, particularly with injectable therapy, contact your veterinarian for guidance on getting back on track.

Completing the full prescribed course of oxytetracycline therapy is essential for successful treatment outcomes. Stopping antibiotic treatment before the infection is fully eliminated allows surviving bacteria to regrow and potentially develop resistance. Even if your dog appears to have recovered completely, continue administering the medication until the entire prescribed course is finished. For ophthalmic infections, continued treatment after visible improvement ensures that all bacteria are eliminated and reduces the risk of recurrence. Your veterinarian will provide guidance on when it is appropriate to discontinue therapy.

Oxytetracycline shares the general side effect profile common to tetracycline antibiotics, though most dogs tolerate the medication well when it is used appropriately. Awareness of potential adverse effects allows pet owners to monitor their dogs during treatment and respond appropriately if problems occur. Most side effects are mild and resolve without intervention, but some require veterinary attention. Your veterinarian will discuss specific risks relevant to your dog's health status and the planned treatment regimen.

Gastrointestinal effects are among the most commonly observed side effects with systemic oxytetracycline administration. Nausea, vomiting, diarrhea, and decreased appetite may occur, particularly with oral formulations. Injectable administration generally causes fewer digestive disturbances than oral therapy but can still occasionally produce gastrointestinal upset. These effects are typically mild and temporary. Administration with food may help reduce digestive symptoms when oral formulations are used, though this can also reduce drug absorption. If gastrointestinal side effects are severe or persistent, consult your veterinarian.

Injection site reactions may occur with intramuscular oxytetracycline administration. Pain, swelling, or irritation at the injection site can develop and typically resolves within a few days. Some oxytetracycline formulations are more irritating to tissues than others. Proper injection technique, including using appropriate needle size and rotating injection sites when multiple doses are required, helps minimize local reactions. Significant swelling, persistent pain, or signs of infection at injection sites should be reported to your veterinarian.

Ophthalmic oxytetracycline ointment may cause temporary mild irritation or blurred vision immediately after application. Some dogs may paw at their eyes or show mild discomfort briefly after the ointment is applied, but this typically resolves quickly. Allergic reactions to ophthalmic preparations, while uncommon, can manifest as increased redness, swelling, or worsening discharge. If eye symptoms worsen rather than improve during treatment, discontinue the ointment and contact your veterinarian, as this may indicate an allergic reaction or an infection not responsive to oxytetracycline.

Serious side effects of oxytetracycline are uncommon but warrant immediate veterinary attention when they occur. Allergic reactions may present as facial swelling, hives, difficulty breathing, or collapse. Photosensitivity, or increased sensitivity to sunlight, can occur with tetracycline antibiotics and may be more pronounced in dogs with light-colored coats or minimal hair coverage. Liver toxicity, though rare, may manifest as jaundice (yellowing of the gums or whites of the eyes), lethargy, or vomiting. Tetracyclines can also cause permanent tooth discoloration in puppies with developing permanent teeth, so the medication is typically avoided in very young dogs when possible. Contact your veterinarian promptly if you observe any unusual or concerning symptoms during oxytetracycline treatment.

Known hypersensitivity or allergy to oxytetracycline or any other tetracycline antibiotic constitutes an absolute contraindication to use of this medication. Dogs that have experienced allergic reactions to any tetracycline should not receive oxytetracycline, as cross-reactivity among drugs in this class is common. Allergic reactions can vary from mild skin irritation to severe anaphylactic responses that can be life-threatening. Pet owners must inform their veterinarian of any previous adverse reactions to antibiotics or other medications, including reactions to topical preparations, to ensure safe antibiotic selection.

Significant liver impairment may contraindicate or require cautious use of oxytetracycline. Tetracycline antibiotics undergo hepatic metabolism, and dogs with compromised liver function may have altered drug handling that increases the risk of adverse effects. Oxytetracycline can potentially cause hepatotoxicity, particularly with high doses or prolonged therapy. Veterinarians typically assess liver function before prescribing tetracyclines in dogs with suspected or known hepatic disease. Kidney impairment is also a consideration, as the drug is partially excreted renally, though oxytetracycline is generally considered less nephrotoxic than some other tetracyclines.

Pregnancy represents a contraindication to systemic oxytetracycline use in dogs. Tetracycline antibiotics cross the placenta and can affect fetal development, particularly causing discoloration of developing teeth and potentially impacting bone formation. These effects occur when the medication is administered during pregnancy, especially during the later stages when fetal teeth and bones are actively developing. Nursing dogs may pass oxytetracycline to puppies through milk, potentially causing similar developmental effects. Alternative antibiotics should be selected for pregnant or lactating dogs whenever possible.

Very young puppies, particularly those with developing permanent teeth, should generally not receive oxytetracycline unless alternative antibiotics are not available or appropriate. Tetracyclines bind to calcium in forming teeth, causing permanent yellow, gray, or brown discoloration. This effect occurs during the period of tooth development, which extends to approximately six months of age in most puppies. The ophthalmic formulation is generally considered safer in this regard as systemic absorption is minimal, but veterinarians still consider the age of the patient when prescribing any formulation. Your veterinarian will weigh the risks and benefits if tetracycline therapy is being considered for a young puppy.

Complete disclosure of all medications, supplements, and treatments your dog is currently receiving is essential before starting oxytetracycline therapy. Drug interactions can significantly impact the effectiveness of the antibiotic, increase the risk of adverse effects, or alter the action of other medications. Your veterinarian needs this information to anticipate potential interactions and adjust the treatment plan accordingly. Even over-the-counter products and dietary supplements can interact with antibiotics.

Divalent and trivalent cations can substantially reduce oral oxytetracycline absorption through chelation. Calcium, magnesium, aluminum, iron, and zinc bind to tetracyclines in the gastrointestinal tract, forming insoluble complexes that are poorly absorbed. Antacids containing aluminum or magnesium, sucralfate, calcium supplements, iron supplements, and mineral-containing products should be administered at least two to three hours apart from oral oxytetracycline. Dairy products and calcium-rich foods can also significantly impair absorption. This interaction is particularly important with oxytetracycline compared to newer tetracyclines like doxycycline, as oxytetracycline absorption is more strongly affected by dietary factors.

Several other medication classes may interact with oxytetracycline. Bactericidal antibiotics such as penicillins and cephalosporins may have reduced effectiveness when used concurrently with bacteriostatic antibiotics like oxytetracycline, though this interaction is primarily a theoretical concern. Barbiturates and certain anti-seizure medications can increase the metabolism of tetracyclines. Methoxyflurane anesthesia should not be used in animals receiving tetracyclines due to the risk of kidney toxicity. Digoxin levels may be increased when used with tetracyclines in some patients.

Monitoring during oxytetracycline therapy depends on the treatment duration, route of administration, and your dog's overall health status. Short courses of injectable therapy or topical ophthalmic treatment in otherwise healthy dogs typically require minimal monitoring beyond observation for side effects and assessment of clinical response. Extended systemic treatment or therapy in dogs with underlying health conditions may warrant periodic evaluation of liver and kidney function. For ophthalmic use, monitoring the response of the eye infection guides treatment decisions. Report any lack of expected improvement, worsening of symptoms, or development of unusual effects to your veterinarian promptly.

General precautions for oxytetracycline use include ensuring accurate body weight measurement for proper systemic dosing and strict adherence to veterinary instructions regarding dose, route of administration, and treatment duration. The wide size range among dogs makes precise weight-based dosing particularly important. Injectable medications must be administered using proper technique to avoid complications. For ophthalmic preparations, proper application technique maximizes effectiveness and minimizes the risk of contaminating the medication tube. Follow-up with your veterinarian as recommended allows assessment of treatment response.

While oxytetracycline does not have specific breed-related contraindications associated with the MDR1 gene mutation, breed considerations remain relevant for overall treatment planning. The MDR1 mutation, common in Collies, Australian Shepherds, and related herding breeds, does not significantly affect oxytetracycline handling. However, complete breed and medical history should still be shared with your veterinarian. Certain breeds may have characteristics that influence practical aspects of administration, such as brachycephalic breeds potentially having more difficulty with oral medications or certain eye conformations affecting ophthalmic ointment application.

Handling and administration precautions help ensure safe use of oxytetracycline. Store medication securely away from children and other pets. Wash hands after handling tablets or after applying ophthalmic ointment. When giving injections, use proper technique as instructed by your veterinarian, dispose of needles safely in appropriate sharps containers, and never reuse needles. For ophthalmic preparations, avoid touching the tube tip to the eye or surrounding skin to prevent contamination. Keep multiple pet households organized to ensure only the prescribed patient receives the medication.

Monitoring your dog during oxytetracycline treatment allows early detection of problems. For systemic therapy, watch for signs of gastrointestinal upset including vomiting, diarrhea, or appetite changes. Monitor injection sites for excessive swelling, pain, or signs of infection. For ophthalmic treatment, observe the affected eye or eyes for improvement in redness, discharge, and comfort. Worsening eye symptoms despite treatment may indicate resistant bacteria, an incorrect diagnosis, or an allergic reaction to the medication. Report any concerning findings or lack of expected improvement to your veterinarian.

Special populations require additional consideration when prescribing oxytetracycline. Geriatric dogs may have age-related changes in liver or kidney function that affect drug metabolism and excretion. Puppies with developing permanent teeth should generally receive alternative antibiotics to avoid tooth discoloration. Dogs with chronic illnesses, particularly those affecting the liver or kidneys, require careful evaluation before tetracycline therapy. Pregnant and nursing dogs should receive alternative antibiotics when possible due to the potential effects on developing puppies.

Proper storage of oxytetracycline products maintains medication effectiveness and prevents accidental exposure. Injectable oxytetracycline solutions should be stored according to the manufacturer's directions, typically at controlled room temperature protected from light. Some products may require refrigeration, so check the label or ask your veterinarian about specific storage requirements. Keep injectable solutions in their original vials and inspect for color changes, cloudiness, or particulates before each use, as these may indicate degradation. Ophthalmic ointments should be stored at room temperature, away from heat and direct light, with caps tightly secured to prevent contamination.

Formulation-specific storage considerations apply to different oxytetracycline products. Injectable solutions typically have expiration dates that should be carefully observed, and multi-dose vials may have limited stability after initial puncture. Terramycin ophthalmic ointment tubes should be kept clean, with the tip wiped with a clean tissue after each use if necessary, and caps replaced immediately. Oral formulations, when available, should be kept in tightly closed containers protected from moisture. All forms of oxytetracycline should be protected from excessive heat, as tetracyclines can degrade when exposed to high temperatures, potentially forming harmful breakdown products.

Safety considerations for oxytetracycline storage include keeping all medications secure from access by children and pets. Injectable preparations include needles that pose additional safety concerns and must be handled and disposed of properly. Dogs may be attracted to flavored oral medications and could potentially access and consume them if given the opportunity, so secure storage is essential. When disposing of unused or expired oxytetracycline, use pharmacy take-back programs when available. Dispose of needles and syringes in approved sharps containers. Never discard injectable medications or sharps in regular household trash where they could pose risks to others.

Oxytetracycline is generally well-tolerated across all dog breeds, with no specific breed-related contraindications comparable to those seen with certain other medications. The MDR1 gene mutation, which causes increased sensitivity to some drugs in Collies, Australian Shepherds, Shetland Sheepdogs, and related breeds, does not significantly affect oxytetracycline metabolism or safety. This makes oxytetracycline a reasonable antibiotic choice in these breeds when tetracycline therapy is indicated. However, your veterinarian should still be informed of your dog's breed background as part of comprehensive medical history taking.

Certain breed characteristics may influence practical aspects of oxytetracycline administration. Breeds with prominent eyes or certain eyelid conformations may be more prone to eye infections and may require more frequent ophthalmic ointment applications or longer treatment courses. Brachycephalic breeds with short faces may have more difficulty with oral medication administration. Breeds known for sensitive digestive systems may experience more pronounced gastrointestinal side effects with systemic oxytetracycline, though this varies considerably among individuals.

Size variations among dog breeds significantly impact systemic oxytetracycline dosing. Toy breeds weighing just a few pounds require precise dose calculations, and even small changes in weight can affect the appropriate dose. Injectable preparations must be drawn up accurately for these small patients. Giant breeds require proportionally larger doses, which may affect treatment costs and the volume of injectable medication needed. Your veterinarian will calculate the appropriate dose based on accurate body weight measurement and select formulations suitable for your dog's size.

Age considerations affect oxytetracycline use regardless of breed. Puppies with developing permanent teeth should generally receive alternative antibiotics when available to avoid permanent tooth discoloration. This precaution is most important for systemic administration, as ophthalmic use results in minimal systemic absorption. Senior dogs of any breed may have age-related changes in organ function that affect drug handling, potentially warranting dose adjustments or enhanced monitoring during treatment. Your veterinarian will consider your dog's age, breed, size, and overall health when determining whether oxytetracycline is appropriate and how it should be administered.

Doxycycline represents the most commonly used tetracycline antibiotic in companion animal medicine and is often preferred over oxytetracycline for systemic infections in dogs. Doxycycline offers advantages including better oral bioavailability, less interference from dietary factors affecting absorption, and superior tissue penetration. For tick-borne diseases such as ehrlichiosis and anaplasmosis, doxycycline is typically the first-line choice. Minocycline is another tetracycline option with properties similar to doxycycline. Tetracycline itself, the original member of this antibiotic class, is available but less commonly used in current veterinary practice due to its pharmacokinetic limitations.

When tetracycline antibiotics are not appropriate or effective, alternative antibiotic classes may be considered based on the specific infection being treated. For eye infections, other ophthalmic antibiotic preparations include those containing neomycin, polymyxin B, bacitracin, gentamicin, ciprofloxacin, or tobramycin. Selection depends on the suspected pathogen and response to initial therapy. For systemic bacterial infections, fluoroquinolones, beta-lactam antibiotics, or other classes may be selected based on culture and sensitivity results when available or empirical knowledge of likely pathogens.

Supportive therapies may complement antibiotic treatment depending on the condition being addressed. For eye infections, cleaning discharge from around the eyes and protecting the eye from further irritation supports healing. Systemic infections may benefit from supportive care including adequate hydration and nutrition. Probiotic supplements can help maintain gastrointestinal health during antibiotic therapy. Any additional treatments or supplements should be discussed with your veterinarian to ensure they do not interfere with the antibiotic therapy and are appropriate for your dog's specific situation.